# Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors

Source: https://onco.cc/trials/nct00003475/  
OnCo record `nct00003475` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Antineoplastons in Brain and spinal cord tumours, run by Burzynski Research Institute, completed.

## Summary

Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors is a phase 2 interventional study registered as NCT00003475 by Burzynski Research Institute, with 40 participants recorded, started 1996-02 and reaching its primary completion in 2011-05. Interventions recorded: Antineoplaston therapy (Atengenal + Astugenal). Conditions recorded: Malignant Brain Tumors.

Linked to the technology Antineoplastons because the registry's title names it ("antineoplastons") and Brain and spinal cord tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00003475
- Phase: 2
- Setting: Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors
- Sponsor: Burzynski Research Institute
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT00003475: https://clinicaltrials.gov/study/NCT00003475

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- technologies: [Antineoplastons (Burzynski clinic)](https://onco.cc/technologies/antineoplastons/)

---
JSON: https://onco.cc/api/v1/entities/nct00003475.json